-

Innovassynth and Actylis partner to address Nucleic Acid Supply Chain Vulnerabilities

A new source of nucleosides, and specifically Phosphoramidites, with full supply chain transparency and diversification

A new partnership between Innovassynth and Actylis, two industry-leading companies offering choice and flexibility

PORT WASHINGTON, N.Y.--(BUSINESS WIRE)--We are excited to announce a new partnership between Innovassynth and Actylis, two industry-leading companies offering Custom synthesis, Contract manufacturing and off-the-shelf products to the Pharmaceutical and Life Sciences industry. This collaboration will allow Actylis to add Innovassynth’s portfolio of nucleosides to its range of critical raw materials.

Innovassynth, India, is a Custom Development & Manufacturing Organization (CDMO) and a trusted partner to Pharma & Drug Discovery, Life Sciences, Diagnostics, and Material Science companies worldwide. They have technological expertise and extensive experience in the field of chemistry, and they provide services from development to commercialization of products. Nucleic acid chemistry is one of Innovassynth’s core competencies, and they have gained a reputation for being a reliable commercial manufacturer of Protected Nucleosides, Phosphoramidites, and Reagents. Their range of Nucleosides includes DNA, RNA, LNA, and GalNAc conjugated derivatives and intermediates with various spacers, linkers, and other building blocks. Innovassynth offers end-to-end manufacturing and a transparent supply chain for Phosphoramidites and a variety of nucleic acid reagents, which is a compelling proposition to customers lacking supply chain diversity. Innovassynth also has significant capability in Process R&D, Custom Synthesis, & Contract Manufacturing of Pharma intermediates, Specialty Chemicals, and Organometallics for customers worldwide.

Actylis has a large technical sales team of chemists globally who understand customers’ nucleoside needs and advise on the best solution to their product challenges. Actylis can offer complementary products to the Innovassynth range through its recently acquired GMP manufacturing capabilities in Europe and the US. Actylis provides local and global distribution in the US and Europe through strategically located warehouses, supply chain and sales offices in over ten countries. Actylis can support its customer's development projects through every milestone in the development cycle from R&D to commercial production.

"We are truly excited to partner with Actylis which will synergize our reach and offer our customers a wider range of solutions. Due to its techno commercial expertise, global sales and distribution network, Actylis has emerged as the trusted partner of choice. We are committed to providing high-quality products and services to our customers, and we believe this partnership is a step in the right direction,” said Dr. Hardik Joshipura, Managing Director and Chief Executive Officer of Innovassynth.

Gilles Cottier, Chief Executive Officer of Actylis, said: “We’ve worked with Innovassynth on several projects over the past couple of years and I’m continually impressed with their capabilities and quality management. They have become a critical outsourcing partner as our internal projects scale. Innovossynth’s backward integrated Phosphoramidite supply chain – all originating in India – from key starters to finished product brings unique value to our customers. Bringing the nucleoside offering to market, together, fills key continuity of supply challenge for our customers and reinforces our position as The Partner of Choice.”

For more information, visit [link.]

Also, we would be happy to host you at Innovassynth booth #821 at TIDES USA – San Diego

Contacts

Paul Staunton
Actylis
pstaunton@actylis.com

Actylis


Release Summary
Innovassynth and Actylis announce a strategic partnership in Life Sciences and Specialty Chemicals.
Release Versions

Contacts

Paul Staunton
Actylis
pstaunton@actylis.com

More News From Actylis

Actylis and Novo Nordisk Pharmatech Announce a Strategic Partnership for the Distribution of Benzalkonium Chloride in Targeted European Countries.

NEW YORK--(BUSINESS WIRE)--Actylis and Novo Nordisk Pharmatech A/S have entered into an agreement for the distribution of pharmaceutical grade Benzalkonium Chloride (BKC) to the pharmaceutical and medical device markets in Germany, Spain, Portugal, UK and Ireland. By combining Novo Nordisk Pharmatech’s leading position as a manufacturer of the highest standards of pharmaceutical grade quaternary ammonium compounds (Quats), with Actylis’ expertise and infrastructure in critical raw material dist...

Actylis Achieves Silver EcoVadis Rating, Demonstrating Commitment to Sustainability Excellence

NEW YORK--(BUSINESS WIRE)--Actylis, a leading global manufacturer of critical raw materials and performance ingredients for the life sciences and specialty chemicals markets, is proud to announce its attainment of a Silver rating from EcoVadis, solidifying its position in the 85th percentile among industry peers. This remarkable achievement underscores Actylis' unwavering commitment to sustainable practices and its dedication to fostering a more responsible and eco-conscious future. What makes...

Actylis Launches a New cGMP WFI Generation, Storage, and Distribution System with Additional ISO Class 7 Manufacturing Space as Part of Its Continued Commitment to Supporting Biopharmaceutical Manufacturing

MONTREAL--(BUSINESS WIRE)--Actylis, a leading global manufacturer of critical raw materials and performance ingredients for the life sciences and specialty chemicals markets, today announced the launch of Water for Injection (WFI) and additional ISO Class 7 manufacturing space at its Baie d’Urfé site in Montreal, Canada. Used for the preparation of media, buffers, and other aqueous solutions, Actylis’ WFI meets monographs for pharmacopoeias worldwide, and can be provided in both custom and stan...
Back to Newsroom